Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Patients with high cholesterol are close to having a new class of drugs to help lower their cholesterol levels. So called PCSK9 inhibitors work in a completely different way than statins, the most popular class of cholesterol-lowering drugs, allowing them to be used in conjunction with the current standard of care in patients that haven't gotten to their cholesterol goal.
Amgen (NASDAQ: AMGN ) is in the lead with evolocumab, but Regeneron Pharmaceuticals (NASDAQ: REGN ) and Sanofi (NYSE: SNY ) , which are jointly developing alirocumab, aren't too far behind. Beyond those two, quite a few drugmakers -- Roche, Pfizer, Novartis, and others -- are taking their own shot at developing PCSK9 inhibitors.
In the video that follows, Max Macaluso, the Fool's health-care bureau chief, and Fool contributor Brian Orelli discuss why the class of PCSK9 inhibitors is worth keeping an eye on and potential pitfalls the companies may face.
More potential hyper growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.